this notion, several approaches have been explored to improve persistence of genetically modified T cells in vivo. For example, the introduction in receptors of intracellular domains from the CD28 and/or CD137 co-stimulatory molecules has led to an increased CAR T cell persistence as well as expansion in vivo, and consequently in clinical responses (6, 7) .
Furthermore, preclinical studies in mice and monkeys suggest that improved in vivo persistence and antitumor responses are obtained when T cells in early stages of differentiation (such as naïve or central memory cells) are used for genetic modification and treatment (8, 9) . In fact, the differentiation state of CD8 + T cells appeared to be inversely related to their capacity to proliferate and persist (10, 11) . We have previously generated CAR T cells directed against carboxy-anhydrase-IX (CAIX) and treated patients with CAIX-positive metastatic renal cell carcinoma (mRCC) (12) . Here, we assessed T cell maturation stage prior to and during CAR T cell expansion cultures, analyzed whether the T cell maturation stage affects CAR expression and function in vitro as well as the in vivo properties of CAR T cells, in particular expansion potential and absolute numbers of circulating CAR T cells.
MaTerials anD MeThODs

Patients and Treatment
Patients, diagnosed with CAIX-positive mRCC and for whom no standard treatment was available, were included in this phase-I trial. Patients were treated in three cohorts, and aimed to assess toxicity and to establish the maximum tolerated dose of the number of CAR T cells. Treatment schedule was previously presented (13) and was, in brief: in cohort 1, treatment consisted of intravenous administration of 2 × 10 7 T-cells at day 1, 2 × 10 8
T-cells at day 2, and 2 × 10 9 T-cells at days 3-5 (treatment cycle 1) and days 17-19 (treatment cycle 2). Simultaneously, patients received twice daily subcutaneous injections of interleukin-2 (IL-2) at 5 × 10 5 IU/m 2 on days 1-10 and days 17-26. Because of liver toxicity (13) , this schedule was changed in cohort 2, to a classic 3 × 3 dose-escalating phase I schedule starting at 1 × 10 8 CAR T-cells per infusion and extending to 2, 4, 8, 16, 20, 25 , and 30 × 10 8 cells at subsequent dose levels, and applying a maximum of 10 T-cell infusions at days 1-5 and days 29-33 combined with sc IL-2 at 5 × 10 5 IU/m 2 twice daily at days 1-10 and days 29-38. In cohort 3, patients were treated as in cohort 2, but received an extra i.v. infusion of 5 mg of the anti-CAIX mAb G250, 3 days before start of each series of CAR T-cell infusions, in order to block CAIX antigen in the liver and leaving accessible CAIX antigen at RCC tumor sites (14) (15) (16) .
For the analyses of CAR T cell persistence, only patients treated in cohorts 2 and 3 were assessed until day 29, as from day 29 eight out of nine patients received a second treatment cycle of CAR T cells. Since patients in cohort 1 received varying numbers of CAR T cells, and one patient already received a second cycle of CAR T cells on days 17-19, cohort 1 was not assessed in the persistence analyses.
Patients did not receive lympho-depleting pretreatment. The clinical protocol and amendments were approved by governmental regulatory authorities (Central committee on research involving Human Subjects) as well as the Erasmus MC institutional medical ethical review board. The clinical protocol (DDHK97-29/P00.0040C) adheres to the Declaration of Helsinki protocols. Patient characteristics are detailed elsewhere (13) .
T cell infusion Product and Post-Treatment Blood sampling
Patient peripheral blood mononuclear cells (PBMC) from leukapheresis (n = 9) were activated at day 0 with soluble anti-CD3 mAb OKT3 (10 ng/mL) without IL-2. At days 2 and 3, T cells were retrovirally transduced with the CAIX CAR in the presence of 100 IU/ml IL-2. From days 4 to 18, T cells were expanded in medium supplemented with 360 IU/ml IL-2. Patients were treated with five daily infusions of "fresh" CAIX CAR T cells harvested from culture at days 14-18 (13, 17) . We obtained blood samples at regular intervals before, during, and after treatment for direct flow cytometric (FCM) analysis and isolation and cryopreservation of PBMC in liquid nitrogen (18, 19) .
Flow cytometry
Carboxy-anhydrase-IX CAR-positive T cells in cultures and blood samples were assessed by FCM using the anti-CAIX CAR idiotype mAb NuH82, as described in Ref. (18) and Figure S1 in Supplementary Material. The starting T cell product (PBMC from leukapheresis) and T cell cultures were analyzed for various lymphocyte subsets, a.o. CD4
+ and CD8 + T cells and T cell maturation subsets using following markers: CD27, CD28, CD45RA, CD45RO, CD62L, and CCR7. The starting T cell product (PBMC from leukapheresis) is referred to the "baseline" sample or measurement in the rest of this study. In addition, T cell maturation subsets were analyzed for CAR-expression ( Figure S1 in Supplementary Material) and CAR-mediated effector function in response to CAIX + RCC cell line (SKRC-17 MW1-clone4) by means of upregulated expression of CD107. Information on antibodies and staining combinations used in multi-color FCM is specified in Table S1 in Supplementary Material. Samples were measured on the FACS Canto, and analyzed with FCS express v. 
statistical analysis
Statistical analyses were performed using SPSS software (version 21) for Windows (IBM Corporation, IL, USA). Graphpad Prism v5.0 was used to prepare graphs. 
resUlTs
T cell Phenotype
cells (TCE + TES). CD4
+ T cells also showed a culture-dependent decrease in the fraction of TN and an increase in the fraction of TEM, yet the most prevalent subset at baseline, i.e., TCM, remained unchanged ( Figure 1C) . Interestingly, in contrast to CD8 + T cells cultured CD4 + T cells harbored almost no TCE cells. Additional analysis with different T cell maturation markers [CD45RA, CCR7 (CD197), and CD62L] showed high concordance with the maturation stages and kinetics as described above ( Figure S4 in Supplementary Material).
caiX car expression in T cell Maturation subsets
At culture day 14, the proportion of CAIX CAR-expressing cells was about equal for various T cell subpopulations, such as CD3 positive T cells in combination with CD4, CD8, CD56, CD57, TCRγδ, CD45RA, CD45RO, CD62L, or CCR7 ( Figure S5 in Supplementary Material). The proportion of CAIX CARexpressing cells within CD8 + and CD4 + T cells was stable during patient treatment (culture days [14] [15] [16] [17] [18] , and appeared highest in the TINT + TCM and lowest in the TES maturation stages (Figures 2A,B) . When considering the CAR expression level per cell (mean fluorescence intensity, MFI), we observed a significant decrease of CAR expression between days 14 and 18 for almost all maturation stages with exception of CD8 +
TN, CD8
+ TES cells, and CD4 + TES cells (Figures 2C,D) . This observation is in extension to a previous report on a general loss of CAR expression during the last 5 days of the T cell culture (20) . Data at MFI level also reinforced the above observation that CAR expression was highest in the TINT + TCM and lowest in the TES maturation stages (Figures 2C,D) . Further, we analyzed the CAIX CAR-mediated function (degranulation) and found no significant differences in CD107-upregulation between the different maturation stages or T cell culture times following co-culture of CAR T cells with a CAIX-positive RCC cell line or CAIX-negative K562 cells. Thus, the relatively small decrease in CAR expression did not result in a measurable decrease in CAR-mediated function (Figures 3A,B) .
T cell Maturation correlates with In Vivo car T cell expansion
We analyzed whether phenotype of T cells at baseline and after culture correlated with numbers of CAR T cells in patient blood and expansion (fold increase) of these CAR T cells during 5 days after the last infusion. Kinetics of circulating CAR T cell numbers irrespective of maturation stage in patients have been reported elsewhere (20) . Here, we reveal a significant correlation between the fold increase in CAR T cell numbers in patients and the proportions of CD8
+ TN cells at baseline ( Figure 4A ) and CD8 + TCE in the infusion product at culture day 14 ( Figure 4B ) and on day 18 [r = 0.683, p = 0.042 (data not shown)]. Patients with higher proportions of CD8 + TN cells in the baseline PBMC and CD8 + TCE in the infusion product, in general, had higher absolute numbers of circulating CAR T cells up to 29 days after the first infusion (Figures 4C,D) . Our in vitro analyses considered both CD8 + and CD4 + T cells (Figures 1-3) . Correlations between the + , CD27/CD28 − ) and TCE (CD45RA + , CD45RO + , CD27/ CD28 − ) cells significantly increased. We noted a shift from TN cells to more maturated stages as was described before for other transduced T cell products cultured with IL-2 (21). Interestingly, also the frequency of TES declined during the CAR T cell culture. We anticipate that the less maturated cells like TCM and TEM have proliferated faster, and thereby have overgrown the TES cells.
We demonstrated a small decline in CAR expression level per cell during the 5-day CAR T cell culture covering the days of T cell administration (days 14-18) that was independent of T cell maturation stage and did not affect CAR-mediated function. We conclude that the five sequential and "freshly" prepared clinical preparations of CAIX CAR T cells had about equal phenotypic and functional properties.
In adoptive CAR T cell treatment, circulating numbers, persistence and in vivo expansion potential of infused CAR T cells are currently the only parameters revealed to be associated with improved clinical outcome (22) . Most CAR T cell trials targeting CD19 in hematological malignancies show strong T cell expansion, mainly due to a high load and accessibility of target antigen, the nature of tumor cells (B cells being able to provide co-stimulation), and highly active (second generation) CAR FigUre 4 | correlations between T cell maturation (pre-infusion) and increase of chimeric antigen receptor (car) T cell numbers in patients. Correlation plots of proportions of TN, TCM, TEM, TCE, and TES cells at baseline (a) and culture day 14 (B) vs. increase of CAR T cell numbers in vivo during the first 5 days after the last T cell infusion of treatment cycle 1 (13, 20) . Dotted lines represent the 95% confidence bands of the best fitted line. The Spearman correlation coefficient method was used to assess linear association. p-Values less than 0.05 were considered significant. Patients were divided into above or below median values (high and low, respectively) of TN at baseline (day 0) (c) or TCE cells at culture day 14 (D) and plotted for absolute numbers of circulating CAR T cells during treatment cycle 1 (days 1-29). See also legend to Figure 1 for further details.
T cells. Along these lines, we sought to define pre-infusion characteristics that may predict the in vivo behavior of infused CAR T cells. Here, we showed that patients with more CD8 + TN cells in baseline PBMC (from leukapheresis) or more CD8
+ TCE in the infusion product at culture day 14, showed a higher fold increase in numbers of CAR T cells in vivo, resulting in higher blood levels of CAR T cells in these patients for at least 4 weeks. In fact, a correlation exists between characteristics of both baseline PBMC (proportion CD8 + TN) and infusion product (proportion CD8 + TCE) and numbers of circulation CAR T cells after treatment. Such findings bear clinical relevance, as younger T cells were shown to positively correlate with clinical effectiveness in adoptive T cell trials (1, 23, 24) . To the best of our knowledge, our study is the first CAR T cell trial targeting a solid tumor, in which a correlation is demonstrated between pre-infusion and pre-expansion T cell characteristics and in vivo CAR T cell expansion potential. In only one other non-CD19 CAR trial, targeting neuroblastoma with GD2 CAR T cells, a correlation was described between in vivo CAR T cell persistence and the proportion of CD4 + or TCM cells in the infusion product (24) . Our observation is in line with the report that effector T cells derived from naive rather than memory T cell subsets possess superior features for adoptive immunotherapy, though no correlations were made with in vivo parameters (25) .
The observation that the proportion CD8 + TN in baseline PBMC determines the in vivo behavior of CAR T cells is intriguing and provides a means to manipulate leukapheresis products for a better clinical outcome, especially for patients with low proportions of TN cells in PBMC. This could include enrichment for TN cells before transduction or changing the culturing conditions by addition of cytokines such as IL-15 and IL-21 during expansion (21, 26) . These data may provide clues to adapt the in vitro T cell processing toward optimal T cell fitness and may enable to develop an improved protocol for adoptive T cell therapy.
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